Astrazeneca plc Overview

Astrazeneca plc Research & Development

Research & Development expenses for AZN.

Quarterly R&D Expenses

$3.86B

↓ 17.43% YoY

As of Dec 31, 2025

Annual R&D Expenses (TTM)

$14.24B

↑ 6.59% YoY

Trailing 12 months ending Dec 31, 2025

Average R&D Expenses (Comparison Companies)

Research & Development History

Research & Development Comparison

Annual Research & Development Growth Rate (%)

Annual Research & Development Growth (Absolute)

Jump to metric

Total Revenue Cost of Revenue Gross Profit Research & Development Selling, General & Admin Operating Income Other Income Expense Net EBIT Income Tax Net Income Profit Margin